Search - tctmd.com

Displaying 341 - 360 of 371

Sort: Relevancy | Date

News Daily News

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

October 17, 2011

News Daily News

Long-term Outcomes Similar for Biodegradable-Polymer, Permanent-Polymer DES

September 12, 2011

News Daily News

ISAR-CABG Published: DES Preferred for Saphenous Vein Graft Lesions

Jason Kahn

September 12, 2011

News Conference News

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

September 02, 2011

News Conference News

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

August 31, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Conference News

New-Generation DES Reduce Restenosis, Stent Thrombosis

August 29, 2011

News Daily News

TRIAS HR Published: Genous Stent Doubles Target Lesion Failure

Leah Lawrence

August 23, 2011

News Daily News

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

L.A. McKeown

August 19, 2011

News Daily News

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

Caitlin E. Cox

August 03, 2011

News Daily News

Meta-analysis Finds Equivalence Between First-, Second-Generation DES

L.A. McKeown

August 02, 2011

News Daily News

Women Have Less Neointimal Hyperplasia Than Men With ZES

Leah Lawrence

July 29, 2011

News Daily News

ISAR-TEST 5 Published: Polymer-Free Dual DES Noninferior to Resolute

Jason Kahn

July 21, 2011

News Daily News

DES Show Advantage over BMS for Heart Transplant Complication

L.A. McKeown

July 01, 2011

News Conference News

Meta-analysis: Biodegradable Polymer DES Reduce Stent Thrombosis, TLR at 3 Years

Caitlin E. Cox

May 20, 2011

News Daily News

Long-term Safety of PCI vs. CABG for Left Main Disease Depends on Syntax Score

May 16, 2011

News Daily News

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

April 20, 2011

News Daily News

Bleeding Increases Mortality as Late as 3 Years After DES

Leah Lawrence

April 18, 2011

News Conference News

ACC Scientific Session-i2 Summit 2011: The Devil Is in the Details

Caitlin E. Cox

April 08, 2011

News Daily News

Pioglitazone Can Decrease Need for Revascularization in Diabetic Patients After BMS

L.A. McKeown

April 07, 2011

Advertisement

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

Long-term Outcomes Similar for Biodegradable-Polymer, Permanent-Polymer DES

ISAR-CABG Published: DES Preferred for Saphenous Vein Graft Lesions

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

Long-term Antiplatelet Therapy: All Risk, No Benefit

New-Generation DES Reduce Restenosis, Stent Thrombosis

TRIAS HR Published: Genous Stent Doubles Target Lesion Failure

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

Meta-analysis Finds Equivalence Between First-, Second-Generation DES

Women Have Less Neointimal Hyperplasia Than Men With ZES

ISAR-TEST 5 Published: Polymer-Free Dual DES Noninferior to Resolute

DES Show Advantage over BMS for Heart Transplant Complication

Meta-analysis: Biodegradable Polymer DES Reduce Stent Thrombosis, TLR at 3 Years

Long-term Safety of PCI vs. CABG for Left Main Disease Depends on Syntax Score

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

Bleeding Increases Mortality as Late as 3 Years After DES

ACC Scientific Session-i2 Summit 2011: The Devil Is in the Details

Pioglitazone Can Decrease Need for Revascularization in Diabetic Patients After BMS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content